Global DNA methylation is altered by neoadjuvant chemoradiotherapy in rectal cancer and may predict response to treatment - A pilot study.

Thumbnail
Name:
Publisher version
Authors
Tsang, J S
Vencken, S
Sharaf, O
Leen, E
Kay, E W
McNamara, D A
Deasy, J
Mulligan, E D
Affiliation
Department of Surgical Research, Connolly Hospital & RCSI, Blanchardstown, Dublin, Ireland. Electronic address: julianst@yahoo.com.
Issue Date
2014-07-28
Keywords
CANCER
MEDICAL TREATMENT
Local subject classification
CANCER, RECTAL
CHEMOTHERAPY
RADIOTHERAPY

Metadata
Show full item record
Citation
Tsang JS et al. Global DNA methylation is altered by neoadjuvant chemoradiotherapy in rectal cancer and may predict response to treatment - a pilot study. Eur J Surg Oncol 2014
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
URI
http://hdl.handle.net/10147/325912
DOI
10.1016/j.ejso.2014.06.008
PubMed ID
25108814
Abstract
In rectal cancer, not all tumours display a response to neoadjuvant treatment. An accurate predictor of response does not exist to guide patient-specific treatment. DNA methylation is a distinctive molecular pathway in colorectal carcinogenesis. Whether DNA methylation is altered by neoadjuvant treatment and a potential response predictor is unknown. We aimed to determine whether DNA methylation is altered by neoadjuvant chemoradiotherapy (CRT) and to determine its role in predicting response to treatment.
Item Type
Article
Language
en
ISSN
1532-2157
Collections